Your session is about to expire
← Back to Search
Wearable Device for Long COVID
N/A
Recruiting
Research Sponsored by Scripps Translational Science Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Is at least 18 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess if wearable devices and education can help people with Long COVID manage their symptoms.
Who is the study for?
This trial is for adults over 18 with a self or physician diagnosis of Long COVID, ME/CFS (chronic fatigue syndrome), or POTS (rapid heartbeat when standing). Participants must own or be willing to use a wearable device for symptom management and agree to share data regularly.
What is being tested?
The study aims to understand Long COVID better by using wearable devices. Participants will receive educational materials and use their own or provided wearables to track symptoms and see if this helps manage post-exertional malaise.
What are the potential side effects?
Since the intervention involves non-invasive monitoring with a wearable device, significant side effects are not anticipated. However, some individuals may experience discomfort from wearing the device continuously.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary Objective 1:Assess the effect of study-provided devices and enhanced educational materials to manage Long COVID-19 symptom severity, compared to general educational materials alone using data from participants survey responses.
Primary Objective 2: Collate a unique longitudinal dataset combining patients' demographics, symptoms, symptom severity, quality of life, and sensor data including sleep, activity, heart rate, heart rate variability, and Body Battery.
Secondary study objectives
Secondary Objective: Assess the longitudinal impact of sustained use of the study-provided devices and enhanced educational materials on symptom severity.
Other study objectives
Exploratory Objective: Assess whether individuals who enroll in the study with their own wrist-worn wearable device and receive educational materials see a decrease in symptom severity and whether this differs by device brand and/or feature.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Treatment: study provided wearablesExperimental Treatment1 Intervention
Following consent and the completion of the baseline assessments the treatment group will be prompted to order their device and receive basic education on symptom management along with the enhanced education on wearable devices.
Group II: Treatment: self provided wearablesExperimental Treatment1 Intervention
Following consent and the completion of the baseline assessments the treatment group will receive basic education on symptom management along with the enhanced education on wearable devices.
Group III: Control: study provided wearablesExperimental Treatment1 Intervention
Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be prompted to order their device and receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
Group IV: Control: self provided wearablesExperimental Treatment1 Intervention
Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Wearable device
2018
N/A
~130
Find a Location
Who is running the clinical trial?
Scripps Translational Science InstituteLead Sponsor
52 Previous Clinical Trials
471,308 Total Patients Enrolled